A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
← catalyst calendarNCT05130437 · readout in 1,203 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
50estimated
Sites
22
Countries
Canada, France, Japan +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-09 | actual | When the study began enrolling |
| Primary completion | 2029-12-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-12-04 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Propionic Acidemia
Intervention
- Biological: mRNA-3927
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs), Serious AEs (SAEs), and AEs Leading to Discontinuation
measured Baseline through End of Study Visit (up to 8 years)
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed